SignatureFD’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $677K | Buy |
2,047
+66
| +3% | +$22.5K | 0.01% | 498 |
|
|
2025
Q4 | $788K | Sell |
1,981
-17
| -0.9% | -$7.52K | 0.01% | 441 |
|
|
2025
Q3 | $911K | Buy |
1,998
+92
| +5% | +$37.5K | 0.01% | 407 |
|
|
2025
Q2 | $622K | Buy |
1,906
+151
| +9% | +$41.8K | 0.01% | 491 |
|
|
2025
Q1 | $474K | Buy |
1,755
+115
| +7% | +$29.6K | 0.01% | 548 |
|
|
2024
Q4 | $386K | Sell |
1,640
-214
| -12% | -$56.3K | 0.01% | 611 |
|
|
2024
Q3 | $510K | Buy |
1,854
+471
| +34% | +$123K | 0.01% | 521 |
|
|
2024
Q2 | $336K | Buy |
1,383
+284
| +26% | +$44.8K | 0.01% | 626 |
|
|
2024
Q1 | $164K | Sell |
1,099
-90
| -8% | -$15K | ﹤0.01% | 917 |
|
|
2023
Q4 | $228K | Buy |
1,189
+14
| +1% | +$2.38K | 0.01% | 743 |
|
|
2023
Q3 | $208K | Sell |
1,175
-493
| -30% | -$94.1K | 0.01% | 733 |
|
|
2023
Q2 | $317K | Buy |
1,668
+223
| +15% | +$44.2K | 0.01% | 596 |
|
|
2023
Q1 | $289K | Sell |
1,445
-159
| -10% | -$33.4K | 0.01% | 605 |
|
|
2022
Q4 | $381K | Buy |
1,604
+59
| +4% | +$12.6K | 0.01% | 498 |
|
|
2022
Q3 | $309K | Buy |
1,545
+1,057
| +217% | +$202K | 0.01% | 526 |
|
|
2022
Q2 | $71K | Sell |
488
-510
| -51% | -$72.4K | ﹤0.01% | 1128 |
|
|
2022
Q1 | $163K | Buy |
998
+75
| +8% | +$11.4K | ﹤0.01% | 810 |
|
|
2021
Q4 | $157K | Sell |
923
-29
| -3% | -$5.39K | ﹤0.01% | 817 |
|
|
2021
Q3 | $180K | Buy |
952
+12
| +1% | +$2.25K | 0.01% | 732 |
|
|
2021
Q2 | $159K | Buy |
940
+136
| +17% | +$19.9K | 0.01% | 757 |
|
|
2021
Q1 | $114K | Sell |
804
-149
| -16% | -$22.4K | 0.01% | 810 |
|
|
2020
Q4 | $124K | Buy |
953
+473
| +99% | +$63.2K | 0.01% | 691 |
|
|
2020
Q3 | $70K | Buy |
480
+245
| +104% | +$34.8K | ﹤0.01% | 836 |
|
|
2020
Q2 | $35K | Buy |
235
+45
| +24% | +$6.07K | ﹤0.01% | 1095 |
|
|
2020
Q1 | $21K | Buy |
190
+141
| +288% | +$16.3K | ﹤0.01% | 1206 |
|
|
2019
Q4 | $6K | Buy |
49
+17
| +53% | +$1.7K | ﹤0.01% | 1587 |
|
|
2019
Q3 | $3K | Hold |
32
| – | – | ﹤0.01% | 1695 |
|
|
2019
Q2 | $2K | Buy |
+32
| New | +$2.46K | ﹤0.01% | 1735 |
|
|
2018
Q4 | – | Sell |
-61
| Closed | -$5K | – | 1930 |
|
|
2018
Q3 | $5K | Hold |
61
| – | – | ﹤0.01% | 1526 |
|
|
2018
Q2 | $6K | Buy |
61
+35
| +135% | +$3.47K | ﹤0.01% | 1502 |
|
|
2018
Q1 | $3K | Buy |
+26
| New | +$3.35K | ﹤0.01% | 1476 |
|
|
2016
Q2 | – | Sell |
-37
| Closed | -$2K | – | 1412 |
|
|
2016
Q1 | $2K | Buy |
+37
| New | +$2.46K | ﹤0.01% | 1136 |
|
|
2015
Q4 | – | Sell |
-20
| Closed | -$2K | – | 1279 |
|
|
2015
Q3 | $2K | Buy |
+20
| New | +$2.22K | ﹤0.01% | 995 |
|
Other funds holding ALNY
VPM
VCM
SignatureFD's ALNY Position: Q1 2026 in Review
SignatureFD increased its Alnylam Pharmaceuticals (ALNY) stake by 3.3% in Q1 2026, buying an estimated $22.5K and bringing the position to 2,047 shares worth $677K. The position accounts for 0.01% of the portfolio, ranked #498.
SignatureFD first reported a position in ALNY in Q3 2015 and has held it in 33 quarters since. The position peaked at $911K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- SignatureFD held 2,047 shares of Alnylam Pharmaceuticals worth $677K as of Q1 2026.
- SignatureFD bought 66 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $22.5K.
- Alnylam Pharmaceuticals made up 0.01% of SignatureFD's portfolio in Q1 2026, its #498 holding.
- SignatureFD first reported a position in Alnylam Pharmaceuticals in Q3 2015 and has held it in 33 quarters since.
- SignatureFD's Alnylam Pharmaceuticals position peaked at $911K in Q3 2025.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.